CN Patent

CN111925304A — 一种用于制备卡利拉嗪的化合物及其制备方法

Assigned to Nhwa Pharmaceutical Corp · Expires 2020-11-13 · 6y expired

What this patent protects

本发明涉及一种用于制备卡利拉嗪的化合物及其制备方法，该方法能够克服现有技术中的缺陷，所用原料及试剂均低毒且廉价易得，反应条件温和，产生的三废较少，同时操作简单安全，收率良好，适于工业化生产。

USPTO Abstract

本发明涉及一种用于制备卡利拉嗪的化合物及其制备方法，该方法能够克服现有技术中的缺陷，所用原料及试剂均低毒且廉价易得，反应条件温和，产生的三废较少，同时操作简单安全，收率良好，适于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN111925304A
Jurisdiction
CN
Classification
—
Expires
2020-11-13
Drug substance claim
No
Drug product claim
No
Assignee
Nhwa Pharmaceutical Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.